miRecule, Inc. is a pre-clinical biotechnology company focused on the development of RNA therapeutics to treat a variety of diseases. miRecule has developed DREAmiR, a genomics-based discovery platform that identifies critical RNA targets in specific subsets of patients that would benefit from treatment. The company then creates proprietary chemically-modified RNA therapeutics with improved pharmacology and utilizes antibodies for targeted delivery to the diseased tissue.